ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
The company issued a corrigendum to its FY 2025-26 Annual Report. This update corrects financial highlights, auditor report details, and capital management tables.
Fischer Medical Ventures will invest ₹49.88 Crore into its three material wholly-owned subsidiaries via rights issues to support capital expansion.
Fischer Medical Ventures published a Chairman's Letter outlining its Radiology, Preventive Healthcare and Wellness segments plus Indonesia and Philippines deployments. No new transaction, order or capital event is announced.
Fischer Medical Ventures Limited has submitted its Annual Report for the financial year 2025-2026 as per SEBI regulations. The document is available on the company website.
Fischer Medical Ventures Limited has scheduled its 33rd Annual General Meeting on September 29, 2026, through video conferencing. The company also announced the e-voting and book closure dates.
Fischer Medical Ventures is building an AI-enabled healthcare platform integrating medical imaging, screening, and hospital digitization. Strategy focuses on vertically integrated IP across magnets, coils, and AI diagnostics.
Fischer Medical Ventures (FMV) presentation outlines a vertically integrated AI healthcare ecosystem spanning medical imaging, screening, and hospital digitization through subsidiaries like Time Medical and FlynnCare.
Fischer Medical Ventures Limited has fixed September 22, 2026, as the record date for its upcoming dividend. The 33rd Annual General Meeting is scheduled for September 29, 2026.
Fischer Medical Ventures Limited appointed Mr. David Yeow as an Additional Independent Director for five years. The company also reconstituted its Audit Committee and scheduled its 33rd AGM.
Fischer Medical Ventures' subsidiary, Time Medical International Ventures, launched the CLARION 64/128-Slice AI-Driven CT System, marking a significant advancement in medical imaging technology.
Fischer Medical Ventures Limited's subsidiary, Time Medical Philippines, was awarded a province-wide digital healthcare project in Catanduanes, Philippines. The project deploys integrated Health Kiosks and management systems.
Fischer Medical Ventures allotted 4,54,210 equity shares to FMV Holdings Pte Ltd upon conversion of warrants. The allotment realized Rs. 0.80 Crore in consideration.
Fischer Medical Ventures allotted 2.05 crore equity shares upon conversion of warrants, raising ₹35.99 crore. The conversion involved both promoter and non-promoter entities.
Fischer Medical Ventures Limited announced the resignation of two Independent Directors, Mr. Roberto M Pagdanganan and Mr. Sanjay Jayantilal Jain, effective August 14, 2026.
Fischer Medical Ventures Ltd reported revenue from operations of ₹81.9 Cr (+250.0% YoY) and net profit of ₹3.8 Cr (-22.4% YoY) for Q1 FY27.
Promoters of Fischer Medical Ventures Limited increased their stake by 0.38% through a preferential allotment following warrant conversion on August 12, 2026.
Fischer Medical Ventures filed its Monitoring Agency Report for the quarter ended June 30, 2026, confirming no deviation in the utilization of preferential issue proceeds.
Fischer Medical Ventures allotted 1.43 crore equity shares upon conversion of warrants. The company received Rs 25.06 crore as consideration for the exercise.
Fischer Medical Ventures allotted 66,31,664 equity shares upon conversion of warrants, raising ₹11.64 Crore from promoters. This conversion increases the company's paid-up equity capital.
Shankar Varadharajan and PACs acquired 23 lakh shares of Fischer Medical Ventures Ltd via warrant conversion. The total holding increased to 63.08%.
Fischer Medical Ventures allotted 23,00,000 equity shares upon conversion of warrants held by a promoter. The company received Rs. 4.04 Crore as consideration.
Fischer Medical Ventures Limited has scheduled a board meeting on August 14, 2026, to consider the company's unaudited standalone and consolidated financial results.
Fischer Medical Ventures' subsidiary, Time Medical India, partnered with Parul Sevashram Hospital to install an AI-enabled portable intraoperative MRI system. This marks the first deployment of their Medharanya Brain Suite.
Fischer Medical Ventures secured CDSCO regulatory clearance to import and distribute the Spincare Portable Wound Care System. This marks India's first approval for a portable electrospun wound system.
Fischer Medical Ventures responded to NSE queries regarding segment details and submission delays for its financial results. The company cited technical issues with the NEAPS portal.
Fischer Medical Ventures Ltd submitted a Reg 74(5) compliance certificate confirming dematerialisation of securities for Q1‑2026. The filing updates the exchange records.
Fischer Medical Ventures Ltd reported revenue from operations of ₹101.1 Cr (+105.5% YoY) and net profit of ₹19.2 Cr (+1376.9% YoY) for Q4 FY26.
Fischer Medical Ventures reported audited FY26 results and recommended a ₹0.05 per share dividend. The board also re-appointed S. Ramanand Aiyer & Co. as internal auditors.
Fischer Medical Ventures recommended a 5% final dividend for financial year 2025-26. Pending shareholder approval, the Rs. 0.05 per share payout reward current investors.
Fischer Medical Ventures Ltd reported revenue from operations of ₹97.7 Cr (+98.6% YoY) and a net loss of ₹7.1 Cr for Q4 FY26.